

1 **Title:** A third vaccine dose equalizes the levels of effectiveness and immunogenicity of
2 heterologous or homologous COVID-19 vaccine regimens

3

4 **Authors:** Nicolas Guibert¹, Kylian Trepât^{2,3}, Bruno Pozzetto^{2,4}, Laurence Josset^{2,5,6}, Jean-
5 Baptiste Fassier¹, Omran Allatif², Kahina Saker³, Karen Brengel-Pesce³, Thierry Walzer^{2*},
6 Philippe Vanhems^{2,7*}, Sophie Trouillet-Assant^{2,3*} on behalf of Lyon-COVID study group[§]

7

8 **Affiliations**

9 ¹Occupational Health and Medicine Department, Hospices Civils de Lyon, Université Claude Bernard
10 Lyon1, Ifsttar, UMRESTTE, UMR T_9405, Lyon University, Avenue Rockefeller, Lyon, France.

11 ²CIRI - Centre International de Recherche en Infectiologie, Université de Lyon, Université Claude
12 Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Université Jean Monnet de Saint-
13 Etienne, Lyon, France.

14 ³Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital,
15 Pierre-Bénite, 69310, France

16 ⁴Laboratoire des Agents infectieux et d'Hygiène, University Hospital of Saint-Etienne, Saint-Etienne,
17 42055, France.

18 ⁵Virology laboratory, Institut des Agents Infectieux, Laboratoire associé au Centre National de
19 Référence des virus des infections respiratoires, Hospices Civils de Lyon, F-69004, Lyon, France.

20 ⁶GenEPII sequencing platform, Institut des Agents Infectieux, Hospices Civils de Lyon, F-69004, Lyon,
21 France

22 ⁷Service D'Hygiène, Épidémiologie, Infectiovigilance et Prévention, Hôpital Édouard Herriot, Hospices
23 Civils de Lyon, Lyon, France

24 *Senior authors equally contributed

25 [§]Study group members are listed in the Acknowledgment section of the paper

26

27 **Correspondence:** Correspondence and requests for materials should be addressed to

28 sophie.assant@chu-lyon.fr

29

30 **Keywords:** SARS-CoV-2; vaccination; heterologous vaccine regimens; breakthrough infection;
31 healthcare workers; antibodies; neutralization

32 **Abstract text:**

33

34 **Background :** To cope with the persistence of the Covid-19 epidemic and the decrease in
35 antibody levels following vaccination, a third dose of vaccine has been recommended in the
36 general population. However, several vaccine regimens had been used initially, and the
37 heterologous ChadOx1-S/BNT162b2 regimen had shown better efficacy and immunogenicity
38 than the homologous BNT162b2/BNT162b2 regimen.

39 **Aim :** We wanted to determine if this benefit was retained after the third dose.

40 **Methods:** We combined an observational study of SARS-COV-2 infections among vaccinated
41 healthcare workers at the University-Hospital of Lyon, France, with an analysis of
42 immunological parameters before and after the third mRNA vaccine dose.

43 **Results:** Following the second vaccine dose, heterologous vaccination regimens were more
44 protective against infection than homologous regimens, but this was no longer the case after
45 the third dose. RBD-specific IgG levels and serum neutralization capacity against different
46 SARS-CoV-2 variants were higher after the third dose than after the second dose in the
47 homologous regimen group, but not in the heterologous group.

48 **Conclusion:** The advantage conferred by heterologous vaccination is lost after the third dose
49 both in terms of protection and immunogenicity. Immunological measurements suggest that
50 heterologous vaccination induces maximal immunity after the second dose, whereas the
51 third dose is required to reach the same level in individuals with a homologous regimen.

52 Introduction

53 In response to the coronavirus disease pandemic, several vaccines were rapidly designed
54 and administered to the population, inducing a protective immunity composed of both
55 neutralizing antibodies and virus-specific T lymphocytes. As multiple vaccines were available,
56 different heterologous combinations of prime/boost doses have been used in patients. This
57 mixing of vaccines was motivated first by the necessary adaptation to limited vaccine supply,
58 but also by the rare observation of vaccine-induced severe adverse reactions with some
59 vaccines. Most studies have reported similar or higher immunogenicity following
60 heterologous primary vaccination involving the Vaxzevria (ChAdOx1nCoV-19, AstraZeneca,
61 Cambridge, United Kingdom) and mRNA vaccines Comirnaty (BNT162b2, BioNTechPfizer,
62 Mainz, Germany/New York, United States) and Spikevax (mRNA-1273, Moderna, Cambridge,
63 United States) compared to homologous vaccination [1–4]. For example, binding and
64 neutralizing antibody titers were similar or greater in the heterologous boosted group
65 compared to the homologous group [5,6]. In addition, we and others reported that the
66 enhanced immunogenicity of the heterologous vaccination regimen was associated with a
67 better protection against SARS-CoV-2 infection[2,7]. However, numerous studies have
68 shown that the level of antibodies, and in particular those neutralizing the virus, gradually
69 decreased following vaccination. This phenomenon, combined with the emergence of viral
70 variants having acquired mutations in the spike viral protein making them less sensitive to
71 vaccine antibodies, led health authorities to recommend the injection of a third booster
72 dose. This booster dose was particularly important in immunosuppressed patients for whom
73 vaccine efficacy was lower. Heterologous vaccine schedules of ChAdOx1-S priming and
74 mRNA booster doses as both second and third doses were not associated with increased risk
75 of serious adverse events compared with homologous mRNA vaccine schedules [8]. Recent

76 reports demonstrated that most COVID-19 vaccines delivered as a third dose booster
77 significantly enhanced both humoral and cellular anti-SARS-CoV-2 immunity [9].
78 Observational studies also suggest that a third dose significantly improves protection from
79 symptomatic infection compared to two doses. A recent meta-analysis reported that
80 heterologous and homologous three-dose regimens work comparably well in preventing
81 covid-19 infections, even against different variants [10]. Nevertheless, a recent report has
82 documented some differences in immunogenicity and protection according to vaccine
83 schedule before third dose [11], suggesting that initial vaccination regimens could imprint
84 spike-specific immunity in the long term, regardless of the booster dose.
85 To address this question, we compared spike-specific immunity and protection against
86 infection conferred by second and third dose of mRNA vaccine in healthcare workers (HCWs)
87 primed with either adenovirus-based ChAdOx1-S or COVID-19 mRNA vaccine.

88

89 **Methods:**

90 **Prevalence of SARS-CoV-2 VOC**

91 SARS-CoV-2 testing of HCWs was performed using routine diagnostic procedures in the
92 Virology laboratory of the Hospices Civils de Lyon, and included: TMA (Aptima™ SARS-CoV-2
93 Assay (Hologic), LAMP (SARS-CoV-2 ID NOW™ (Abbott), and RT-qPCR with different kits
94 (Cobas® 6800 SARS-CoV-2 assay (Roche), Panther Fusion SARS-CoV-2 assay (Hologic). To
95 determine the prevalence of SARS-CoV-2 VOC in HCW, available positive samples with Ct<28
96 were sequenced using COVIDSeq (Illumina) as previously described [12]. Libraries were
97 sequenced to 1 M paired-end reads (2x100 bp) and data were analyzed using the in-house
98 seqmet bioinformatic pipeline (available at <https://github.com/genepii/seqmet>). Clades and

99 lineages were determined on samples with genome coverage >90% using Nextclade and
100 PangoLEARN, respectively.

101

102 **Ethical statement and cohort description**

103 ***Population of HCW from the hospital database included in the epidemiological investigation***

104 We extracted data from the occupational medicine database of the University Hospital of
105 Lyon (Hospices Civils de Lyon), France. A total of 13489 HCWs working at Hospices civils de
106 Lyon throughout the study period (12/15/21 _ 03/21/22) were included. Only subjects who
107 (i) had never contracted COVID-19, (ii) were primed with ChAdOx1-S-nCoV-19 or an mRNA
108 vaccine and (iii) received the second or third dose of an RNA vaccine were included in the
109 epidemiological analysis (Supplementary Figure 1). Breakthrough infections, documented by
110 positive RT-PCR or antigenic tests and that occurred after the 15th of December 2021 and at
111 least 7 days after vaccine injection were taken into account to evaluate infection risk in
112 different groups of subjects. Due to the mandatory SARS-CoV-2 vaccination for HCWs in
113 France, we have no missing data regarding this variable. Moreover, the declaration of SARS-
114 CoV-2 infection is compulsory for all staff to obtain daily allowances without loss of salary
115 during the imposed quarantine.

116 The use and analysis of data from the occupational health medical file were authorized after
117 a regulatory declaration to the National Commission for Information Technology and Civil
118 Liberties according to the reference methodology (declaration MR004 number 20-121 of
119 April 30th 2020).

120 ***Population included in the immune response investigations***

121 Eighty-eight naive HCWs for COVID-19 and vaccinated with BNT and/or ChAd and/or mRNA-
122 1273 vaccines were included in a prospective longitudinal cohort study conducted at the
123 Hospices Civils de Lyon. Blood sampling was performed before vaccination, before and
124 4 weeks after the second and the third dose of vaccine. The absence of previous SARS-CoV-
125 2 infection was confirmed using the Abbott SARS-CoV-2 anti-N Ab total assay in all samples
126 (Abbott Diagnostics, Abbott Park, Illinois, United States). Demographic characteristics and
127 delays between doses are depicted in **Supplementary Table 1**.

128 **Measurement of IgG titers**

129 Serum specimens were immediately stored at -80°C after blood sampling. RBD-specific IgG
130 antibodies were measured using bioMérieux Vidas SARS-CoV-2 IgG diagnosis kits, according
131 to the manufacturers' recommendations. For standardization of these assays to the first
132 World Health Organization international standard, the concentrations were transformed into
133 binding antibody units per ml ($\text{BAU}\cdot\text{ml}^{-1}$) using the conversion factors provided by the
134 manufacturers.

135 **Live-virus neutralization experiments**

136 A plaque reduction neutralization test (PRNT) was used for the detection and titration of
137 neutralizing antibodies as previously described [13]. Neutralization was recorded if more
138 than 50% of the cells present in the well were preserved. The neutralizing titer was
139 expressed as the inverse of the higher serum dilution that exhibited neutralizing activity; a
140 threshold of 20 was used (PRNT_{50} titer ≥ 20). All experiments were performed with a subset
141 of sera specimens collected longitudinally from 15 subjects in each group. The different viral
142 strains that were used were sequenced and deposited at GISAID
143 (<https://www.gisaid.org/>) (accession numbers EPI_ISL_1707038 19A (B.38 lineage); EPI_
144 ISL_1904989 Delta (B.1.617.2 lineage); and EPI_ISL_7608613 Omicron (B.1.1.529 lineage)).

145

146 **Statistical analysis**

147 The descriptive statistics generated appropriate figures and parameters according to type of
148 variable (i.e. continuous or categorical). The comparisons between groups were done using
149 the Chi-square test for categorical variables and non-parametric test or student T test
150 according to the distribution for continuous variables. The cumulative probability of COVID-
151 19 was based on the Kaplan-Meier survival analysis and survival distributions were
152 compared using the LogRank test. A univariate and multivariate Cox proportional hazard
153 model was performed to identify the determinants independently associated with onset of
154 COVID-19 according to their hazard ratio (HR) and their 95% confidence interval (95% CI).
155 All *P*-values were two-tailed. $P < 0.05$ was considered as statistically significant. For the
156 immunological part, we used a multiple linear regression model, with adjustment variables
157 (age or age groups, sex, delay, vaccination scheme).

158

159 **Results**

160 *Vaccine effectiveness in HCWs*

161 To compare the risk of SARS-CoV-2 infection following a second or third dose of COVID-19
162 mRNA vaccine (the Pfizer-BioNTech mRNA vaccine, BNT162b2, or the Moderna mRNA
163 vaccine, mRNA-1273) in subjects who received a priming dose of ChAdOx1-S or BNT162b2
164 vaccine, we extracted data from the occupational medicine database of the University
165 Hospital of Lyon (Hospices Civils de Lyon, HCL), France. We focused on individuals not
166 previously infected with SARS-CoV-2 (PCR diagnosis) before vaccination to avoid any bias
167 linked to hybrid immunity (**Figure 1**). Infection rates were monitored in HCWs after the
168 second or the third booster dose in each group. We extracted SARS-CoV-2 infection incident
169 events documented by positive antigenic or RT-PCR tests that occurred between December
170 15th 2021 and 21st March 2022. This period corresponds to the Omicron (lineage BA.1, Clade

171 21K) wave, succeeding to Delta (lineage B.1.1.529, Clades 21I and 21J), and preceding the
172 Omicron sub-lineage BA.2 (Clade 21L) appearance and increase (**Figure 2A-B**). The
173 proportion of SARS-CoV-2 variants of concern (VOC) determined by whole genome
174 sequences in samples collected in HCWs working at Hospices Civils de Lyon during this
175 period was: 70/834 (8.4%) 21J (Delta), 708/834 (84.9%) 21K (Omicron BA.1), and 56/834
176 (6.7%) 21L (Omicron BA.2). **Figure 2C-D** shows the cumulative incidence of breakthrough
177 infections in each group. Following the second vaccine dose, heterologous vaccination
178 regimens were more protective against infection compared to the homologous regimen
179 group (**Figure 2C**). Indeed, after adjustment on age, sex and delay between last vaccination
180 and the start of the study, individuals vaccinated with mRNA vaccines were twice as likely to
181 be infected than those vaccinated with ChAdOx1-S followed by mRNA vaccine (adjusted
182 hazard ratio of 1.88 [1.18- 3.00], p-value =0.008, **Figure 2E**). After the third dose, the number
183 of infections was lower than after the second dose in both vaccination groups, showing the
184 benefit of the boost. Moreover, in the homologous group, the third dose achieved at least
185 the same level of protection as in the heterologous group as demonstrated by the inversion
186 of the infection incidence curves (adjusted hazard ratio of 0.86 [0.72 – 1.02], p-value =0.082,
187 **Figure 2F**). We also conducted an analysis of the infection risk according to the parameters
188 of vaccination, sex or age class. This analysis confirmed the importance of the vaccination
189 schedule after the second dose but not after the third (**Figure 2G-H**). It also shows that in
190 this cohort of vaccinated HCWs, middle-aged females had a higher risk of infection.

191

192 *Analysis of immune response after heterologous and homologous vaccination*

193 We then sought to compare the immunogenicity of the third dose in heterologous vs
194 homologous vaccination groups. For this, we took advantage of the *Covid-Ser* cohort that we

195 previously described and which includes a subset of voluntary healthcare workers in whom
 196 anti-SARS-CoV-2 immunity is measured longitudinally over time (**Figure 3**)[2]. We formed
 197 groups who had received a homologous or heterologous vaccination regimen and who had
 198 received a third dose of mRNA vaccine (**Table 1**).

199

	HCWs primed with BNT (homologous) n=58	HCWs primed with ChadOx (heterologous) n=30	p.adj
Male sex. n	11	6	>0.9999
Age. Year. Median [IQR]	50.50 [41.00-59.00]	38.00 [30.50-41.00]	<0.0001
Body Mass Index *. n	55	29	
Median [IQR]	24.22 [22.12-29.72]	20.94 [20.06-23.88]	0.0077
Delay between first and second dose. Day. Median [IQR]	28 [28-30]	85 [84-85]	<0.0001
Delay between second and third dose. Day. Median [IQR]	266 [245-284]	206 [195-213]	<0.0001
Third dose Moderna. n	5	3	>0.9999
Presence of comorbidity. n	29	10	0.5828
Description of comorbidities			
Hypertension. n	2	0	>0.9999
Diabetes. n	2	0	>0.9999
Cancer. n	1	0	>0.9999
Hypothyroidy. n	4	1	>0.9999
Rheumatic diseases. n	1	0	>0.9999
Chronic respiratory problems. n	4	0	0.7200
Others. n	5	0	0.5480
Currently smoker. n	14	6	>0.9999
Alcohol consumption. n	8	6	>0.9999

*Missing data

200 **Table 1:** Clinical characteristics of patients in the Covid-Ser study (immunological analysis)

201 For alcohol consumption, this was defined as consumption at least once a week. Wilcoxon-Mann-Whitney two-
 202 sided tests were used for quantitative variables and Chi-square or Fisher were used for qualitative variables
 203 when appropriate. Adjusted P values were calculated using the Benjamini-Hochberg method.

204

205 Subsequently, we measured the increase in anti-RBD IgG antibody levels four weeks after
206 the third dose in both groups. No significant difference was observed ($p=0.14$) (**Figure 4A**).
207 We then evaluated the neutralization capacity of serum antibodies against SARS-CoV-2
208 variants 19A, Delta and Omicron four weeks after the third dose. No significant difference in
209 neutralization was observed between the homologous and heterologous schedules (19A:
210 median [IQR] 960 [320-1920] vs. 640 [320-1920]; Delta: 240 [120-480] vs. 320 [160-960];
211 Omicron: 160 [60-640] vs. 160 [80-480], respectively) (**Figure 4B**). Moreover the anti-RBD
212 IgG level is not different in the two groups after the third dose ($p=0.18$) (**Figure 4C**).
213 Data in **Figure 2** show that the heterologous ChAdOx1-S/COVID-19 mRNA vaccine
214 combination confers better protection against SARS-COV-2 infection than the homologous
215 COVID-19 mRNA vaccines combination, but that the third dose equalizes the efficacy of both
216 vaccine regimens. To understand why the advantage of heterologous vaccination is no
217 longer observed after the third dose, we compared humoral immunity four weeks after the
218 second and after the third dose in each group. In subjects vaccinated according to the
219 homologous regimen, the anti-RBD IgG level measured 4 weeks post second dose was
220 significantly lower ($p<0.0001$) than that measured post third dose (1490 [969-2994] BAU/mL,
221 3336 [1795-4491] BAU/mL respectively) (**Figure 4D**) whereas in subjects vaccinated
222 according to a heterologous scheme, no difference was observed (2277 [1520-3400] BAU/mL
223 vs 2242 [1321-3602] BAU/mL respectively) (**Figure 4E**). In addition, for the homologous
224 vaccine group, the antibody neutralizing capacity 4 weeks post third dose was at least 3
225 times higher than that observed 4 weeks post second dose (at least $p<0.01$). In contrast, in
226 heterologous vaccinated individuals, no benefit in neutralizing capacity against 19A and
227 Delta at 4 weeks post third dose was observed. Only the neutralizing capacity of the total
228 antibodies 4 weeks post third dose against Omicron increased 2-fold compared to that 4

229 weeks post second dose ($p < 0.01$) (**Figure 4F-G**). Of note, there is no difference of anti-SARS-
230 CoV-2 IgG level 4 weeks post third dose between HCWs boosted with BNT162b2 ($n=80$) or
231 mRNA-1273 ($n=8$) vaccine ($p=0.30$).

232

233 **Discussion**

234 We previously showed that the heterologous ChAdOx1-S/BNT162b2 combination confers
235 better protection against SARS-CoV-2 infection than the homologous BNT162b2/BNT162b2
236 combination in a real-world observational study conducted in HCWs [2]. Both combinations
237 induced strong anti-spike antibody responses but serum specimens from heterologous
238 vaccinated individuals displayed a stronger neutralizing activity, regardless of the SARS-CoV-
239 2 variant [14]. Here, we asked whether the advantage conferred by the heterologous
240 regimen is conserved after a booster dose of mRNA-based COVID-19 vaccine. Our results
241 show that (i) the third dose with an mRNA vaccine equalizes the levels of effectiveness of
242 heterologous or homologous COVID-19 vaccine regimens and (ii) that serum neutralization
243 capacity against different SARS-CoV-2 variants is comparable four weeks after the boost in
244 both groups. Indeed, the third vaccine dose does not increase antibody levels and
245 neutralization capacity beyond those observed one month after the second dose in the
246 heterologous group, which suggests that a maximal immunity level one month post
247 vaccination is already reached after the second dose in this group and that it cannot be
248 boosted further, at least with an mRNA-based vaccine. While we cannot exclude that a
249 shorter delay between the second and third doses would have a different impact in
250 heterologous vs homologous groups, our results are in line with those of Accorsi et al. who
251 showed that a single booster dose of an mRNA Covid-19 vaccine in individuals who received
252 primary vaccination with a single-dose of adenovirus-based vaccine Ad26.COV2.S, provided

253 protection close to that of the three-dose mRNA vaccine regimen [15]. In addition, Behrens
254 et al. reported that inferior SARS-CoV-2 specific immune responses following homologous
255 ChAdOx1-S / ChAdOx1-S vaccination compared to ChAdOx1-S /BNT162b2 can be
256 compensated by heterologous BNT vaccination as third dose [16]. In our study, only the
257 neutralization of the Omicron variant was slightly better one month after the third dose in
258 the heterologous regimen compared to the second dose. The significance of this result is not
259 clear since the neutralization of the other variants was not changed.

260 More largely, our results address the question of the number of vaccine boosts that are
261 needed to reach the maximal immunity level against SARS-CoV-2, including its numerous
262 variants. We confirm that, using the heterologous combination performed in our study, a
263 single boost is enough to reach this plateau. By contrast, the homologous scheme using an
264 mRNA vaccine needs two boosts for reaching the same level of protection. Of course, this
265 maximum immunity is temporary and decreases with time, which makes the third dose
266 necessary in the heterologous group as well. The recent study of Regev-Yochay et al. that
267 evaluated the benefit of a third boost in an homologous mRNA immunization scheme
268 suggests that a maximum immunity is reached after the third dose with homologous mRNA
269 vaccination. The fourth mRNA vaccine dose seems to be able to restore the level of
270 immunity, but does not quantitatively and qualitatively improve the humoral immunity
271 conferred by the first 3 doses [17].

272 Surprisingly, our data highlighted a higher risk of infection in women between 30 and 50
273 years compared to older HCW. This group of individuals mainly corresponds to active nursing
274 staff with higher exposure to pathogens. Indeed, in the Lyon University hospital, the pattern
275 of contacts (frequency and duration) between nurses and patients and within nurses is
276 superior than for other professionals [18], and this pattern could result in a higher exposure

277 to pathogens, as previously reported in a study of nosocomial influenza spreading at the
278 hospital [19]. Obviously, this higher exposure of middle-aged women is specific to the HCW
279 community and may not apply to the general population.

280 Some limitations of the present study should be acknowledged. First, these results were
281 obtained from observational data and not from a randomized clinical trial. As a result there
282 were some inherent differences between the compared groups. For example subjects
283 vaccinated with a heterologous schedule were on average younger than those vaccinated
284 with a homologous schedule. This difference is explained by the recommendations for
285 vaccination according to which individuals under 55 years of age who received a first dose of
286 ChAdOx1-S should receive a boost of COVID-19 mRNA vaccine. Yet, our statistical analysis
287 did not show a significant impact of age in infection risk or vaccine-induced immune
288 parameters. Second, the HCWs might slightly differ from the general population since they
289 exhibit repeated exposures to SARS-CoV-2, together with close monitoring regarding vaccine
290 coverage and COVID-19 incidence. Third, in our study, the advantage of the heterologous
291 regimen observed after the second dose may be impacted by the delay between the first
292 and second dose which was only of 4 weeks between the first two doses in the homologous
293 scheme. A study by Payne et al. reported that an extended delay of 10 weeks between the
294 first two doses of BNT162b2 allowed the development of better humoral immunity [20].
295 Fourth, the present study was limited to HCWs having no history of SARS-CoV-2 infection
296 prior to vaccination. The benefit of booster dose of mRNA vaccine in patients primed with
297 ChAdOx1-S or mRNA vaccine would need further investigations in people previously infected
298 by different variants. Finally, even if HCWs were heavily tested during the monitoring period
299 of our study, asymptomatic infections may have remained unnoticed.

300 Taken together, our data provide evidence to understand the number of vaccine boosts that
301 are needed to reach the maximal immunity level against SARS-CoV-2 in heterologous or
302 homologous vaccine scheme. More studies will be needed to determine if another vaccine
303 type should be given to boost even further SARS-CoV-2 immunity.

304

305 **Ethical statements_**

306 For the Covid-Ser study, clinical data were recorded by a trained clinical research associate
307 using Clinsight software (v.Csonline 7.5.720.1). Written informed consent was obtained from
308 all participants. Ethics approval was obtained from the national review board for biomedical
309 research in April 2020 (Comité de Protection des Personnes Sud Méditerranée I, Marseille,
310 France; ID RCB 2020-A00932-37), and the study was registered at ClinicalTrials.gov
311 (NCT04341142).

312 References

- 313 1. Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, et al. Immunogenicity and
314 reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. *Nat Med*, 2021;
315 27(9):1530-5.
- 316 2. Pozzetto B, Legros V, Djebali S, Barateau V, Guibert N, Villard M, et al. Immunogenicity
317 and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. *Nature*, 2021;
318 600(7890):701-6.
- 319 3. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and
320 immunogenicity of heterologous versus homologous prime-boost schedules with an
321 adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind,
322 randomised, non-inferiority trial. *The Lancet*, 2021; 398(10303):856-69.
- 323 4. Klemis V, Schmidt T, Schub D, Mihm J, Marx S, Abu-Omar A, et al. Comparative
324 immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and
325 BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. *Nat*
326 *Commun.* 2022; 13(1):4710.
- 327 5. Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, et al. Safety,
328 reactogenicity, and immunogenicity of homologous and heterologous prime-boost
329 immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. *Lancet*
330 *Respir Med.* 2021; 9(11):1255-65.
- 331 6. Niyomnaitham S, Quan Toh Z, Wongprompitak P, Jansarikit L, Srisutthisamphan K,
332 Sapsutthipas S, et al. Immunogenicity and reactogenicity against the SARS-CoV-2 variants
333 following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and
334 BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in
335 healthy Thai adults. *Human Vaccines & Immunotherapeutics.* 2022; 2091865.
- 336 7. Mayr FB, Talisa VB, Shaikh O, Yende S, Butt AA. Effectiveness of Homologous or
337 Heterologous Covid-19 Boosters in Veterans. *N Engl J Med.* 2022; 386(14):1375-7.
- 338 8. Andersson NW, Thiesson EM, Laursen MV, Mogensen SH, Kjær J, Hviid A. Safety of
339 heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-
340 1273 vaccines: nationwide cohort study. *BMJ.* 2022; 378:e070483.
- 341 9. Lustig Y, Gonen T, Meltzer L, Gilboa M, Indenbaum V, Cohen C, et al. Superior
342 immunogenicity and effectiveness of the third compared to the second BNT162b2
343 vaccine dose. *Nat Immunol.* 2022; 23(6):940-6.
- 344 10. Au WY, Cheung PPH. Effectiveness of heterologous and homologous covid-19 vaccine
345 regimens: living systematic review with network meta-analysis. *BMJ.* 2022; 377:e069989.
- 346 11. Liu X, Munro APS, Feng S, Janani L, Aley PK, Babbage G, et al. Persistence of
347 immunogenicity after seven COVID-19 vaccines given as third dose boosters following
348 two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the
349 COV-BOOST trial. *J Infect.* 2022; 795-813.

- 350 12. Detection and prevalence of SARS-CoV-2 co-infections during the Omicron variant
351 circulation, France, December 2021 - February 2022 | medRxiv. DOI:
352 10.1101/2022.03.24.22272871v1
- 353 13. Saade C, Gonzalez C, Bal A, Valette M, Saker K, Lina B, et al. Live virus neutralization
354 testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1
355 and 20H/501Y.V2 isolates of SARS-CoV-2. *Emerg Microbes Infect.* 2021; 10(1):1499-502.
- 356 14. Lee HK, Go J, Sung H, Kim SW, Walter M, Knabl L, et al. Heterologous ChAdOx1-
357 BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses
358 that includes Omicron. *iScience.* 2022; 25(6):104473.
- 359 15. Accorsi EK, Britton A, Shang N, Fleming-Dutra KE, Link-Gelles R, Smith ZR, et al.
360 Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron. *New*
361 *England Journal of Medicine.* 2022; 386(25):2433-5.
- 362 16. Behrens GMN, Barros-Martins J, Cossmann A, Ramos GM, Stankov MV, Odak I, et al.
363 BNT162b2-boosted immune responses six months after heterologous or homologous
364 ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. *Nat Commun.* 2022;
365 13(1):4872.
- 366 17. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. Efficacy
367 of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron. *N Engl J Med.* 2022;
368 386(14):1377-80.
- 369 18. Vanhems P, Barrat A, Cattuto C, Pinton JF, Khanafer N, Régis C, et al. Estimating Potential
370 Infection Transmission Routes in Hospital Wards Using Wearable Proximity Sensors.
371 Viboud C, éditeur. *PLoS ONE.* 2013; 8(9):e73970.
- 372 19. Voirin N, Payet C, Barrat A, Cattuto C, Khanafer N, Régis C, et al. Combining high-
373 resolution contact data with virological data to investigate influenza transmission in a
374 tertiary care hospital. *Infect Control Hosp Epidemiol.* 2015; 36(3):254-60.
- 375 20. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al. Immunogenicity
376 of standard and extended dosing intervals of BNT162b2 mRNA vaccine. *Cell.* 2021;
377 184(23):5699-5714.e11.

378

379 **Figure legends**

380 **Figure 1:** Flow chart of the epidemiological study.

381 The flow chart indicates how individuals with two (left) or three vaccination doses (right)
382 were selected from the total HCW population according to the indicated criteria of
383 exclusion.

384

385 **Figure 2:** The superior efficacy of heterologous vaccination is lost after the third vaccine dose
386 (A) Weekly SARS-CoV-2 testing (n= 2,113 positive samples / 7,863 negative samples) and (B)
387 Variant of concern (VOC) circulation (B) among HCW (n=834 samples with whole genome
388 sequence (WGS) between Dec 15th, 2021 and March 21st, 2022 at Lyon University Hospitals.
389 (C-D) Graphs show the cumulative probability of COVID-19 infection within 100 days after a
390 2nd (C) or a 3rd (D) mRNA vaccine dose in health care workers at Lyon university hospital
391 primed with BNT162b2 (blue line, homologous vaccination, 3074 and 6436 HCWs
392 respectively) or ChAdOx1-S vaccine (brown line, heterologous vaccination, 328 and 1160
393 HCWs respectively). P-value was calculated using Logrank test. (E-F) Forest Plots depict
394 multivariate Cox proportional hazard ratio (IC95%) for COVID-19 infection after a 2nd (E) or a
395 3rd (F) mRNA vaccine dose in health care workers. Hazard Ratio (HRs) were calculated with
396 the HR of 1.0 of the reference stratum, references were indicated for all comparisons. All
397 SARS-CoV-2 infection events documented by positive SARS-CoV-2 RT-PCR or antigenic test
398 were recorded by the service of occupational medicine, Hospices Civils de Lyon.

399

400 **Figure 3:** Design of the “Covid-Ser” study

401

402 **Figure 4:** The booster dose equalizes the levels of immunogenicity of heterologous or
403 homologous vaccine regimens


404 Sera from naïve HCWs vaccinated primed with the BNT162b2 (n=58) or ChadOx1-S vaccine,
405 n=30) and who received an mRNA vaccine for 2nd and 3rd dose were selected. (A) RBD-
406 specific IgG levels were quantified just before and four weeks post booster (third) dose.
407 Concentrations are expressed in binding antibody units per ml (BAU/ml), and data show the
408 difference in RBD-specific IgG levels between the two time-points (missing value for pre-
409 vaccination time point for 11 and 4 patients vaccinated with homologous and heterologous
410 regimen respectively). (B) A subset of 15 sera from both groups four weeks after the third

411 dose were assayed in duplicate for their capacity to neutralize infection of Vero E6 cells by
412 different SARS-CoV-2 strains, as indicated. (C) Comparison of serum RBD-specific IgG levels 4
413 weeks after the 3rd dose between homologous and heterologous vaccine recipients (D-E)
414 Serum RBD-specific IgG levels were measured 4 weeks after the 2nd or after the 3rd dose in
415 the homologous (D) or heterologous (E) vaccine recipients. (F-G) Comparison of the
416 neutralizing capacity of total antibodies collected 4 weeks after the 2nd or after the 3rd dose
417 in the homologous (F) or in the heterologous (G) vaccine group (n=15 for each group). The
418 dashed lines represent the limit of detection (20 in PRNT₅₀). In all graphs, data are
419 represented as box-and-whiskers plots using the Tukey method which show median
420 (horizontal line inside the box), interquartile (25%-75% - upper and lower horizontal lines of
421 the box), and each dot corresponds to one subject. Statistics were calculated using a
422 multiple linear regression model with adjustment variables (age and sex, and when
423 appropriate delay between second and third dose).
424


Figure_1

Two doses of vaccines

medRxiv preprint doi: <https://doi.org/10.1101/2023.02.13.23285853>; this version posted February 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Three doses of vaccines



Figure_2


A.



SARS-CoV-2 test

Negative
 Positive


B.




CLADE

21J (Delta)
 21K (Omicron)
 21L (Omicron)


C.




D.




E.




F.



Figure_3




Naïve vaccinated subjects



Serological investigation


IgG anti-RBD



RBD: receptor binding domain

Live virus neutralization assay

PRNT₅₀



Vero E6 cells



19A



Delta variant



Omicron variant

PRNT₅₀: 50% plaque reduction neutralization test



Adenoviral vaccine (ChAdOx1-S)



mRNA vaccine (BNT162b2 or mRNA-1273)

Figure_4

● Homologous
● Heterologous

